Navigation Links
New Melanoma Drug May Extend Survival
Date:6/25/2012

MONDAY, June 25 (HealthDay News) -- New research suggests that a new drug does a better job of combating advanced skin cancer in melanoma patients than chemotherapy.

However, patients typically still got worse after only a few months on the drug.

The drug, called dabrafenib, blocks a signaling protein and is used to treat melanomas with a specific genetic mutation. About half of melanoma patients have this mutation.

In a phase 3 trial funded by the drug's maker, GlaxoSmithKline, an international group of researchers led by Dr. Axel Hauschild of the Schleswig-Holstein University Hospital in Kiel, Germany, gave dabrafenib or the most common existing treatment, dacarbazine (DTIC-Dome), to 250 patients with spreading or inoperable melanoma. About half responded partially (47 percent) or fully (3 percent) to dabrafenib; the response rate among the dacarbazine group was just 6 percent.

Those who took the new drug survived for an average of 5.1 months without getting worse; 2.7 percent of those treated with the existing drug did the same.

The study authors report that the new drug had few side effects, and those related to the skin appeared to be less severe than in patients on a similar drug called vemurafenib (Zelboraf). That drug is now available in the United States.

It's not clear if the drug will affect overall survival rates. "This trial is good news for our patients with metastatic melanoma. Competition in the field is appreciated since it accelerates new clinical trials, particularly in the combinational setting," Hauschild said in a news release from The Lancet, which published the study online June 25.

"This trial is a major step forward in the run for an improvement of the survival for this disease, which was thought to be untreatable for decades," he added.

Dr. Vernon K. Sondak, chair of the department of cutaneous oncology at the Moffitt Cancer Center in Tampa, said treatments for melanoma have been lacking. New so-called "targeted" drugs like dabrafenib have shown promise, he added, "but all these targeted therapies have a weakness, and that is the eventual development of resistance in the tumor cells."

Still, the research into various drugs "opens up new possibilities for combination therapies that may be even more effective, potentially without causing increased side effects," he said.

As for cost, Sondak said melanoma treatments have been so expensive that health agencies in some countries have refused to pay for them.

More information

For more about melanoma, try the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Vernon K. Sondak, M.D., surgeon and chair, department of cutaneous Oncology, Moffitt Cancer Center, Tampa; June 25, 2012, The Lancet, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Surgery Rates Rising for Non-Melanoma Skin Cancer: Study
2. Moffitt Cancer Center researchers working at frontiers of melanoma research
3. Women More Likely to Survive Melanoma Than Men: Study
4. Scientists Map Melanomas Genome
5. Two-Drug Combo May Be Safe for Melanoma Treatment
6. Melanoma a Big Threat to Older Men
7. Fish shed light on human melanoma
8. LA BioMed investigators, Drs. Kevin Bruhn and Noah Craft, develop novel treatment for melanoma
9. Healthy Behaviors Extend Life After Cancer, Experts Say
10. Exercise and a healthy diet of fruits and vegetables extends life expectancy in women in their 70s
11. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Melanoma Drug May Extend Survival
(Date:6/22/2017)... ... 22, 2017 , ... The VA Maryland Health Care System ... awarded the Baltimore VA Medical Center, a division of the VA Maryland Health ... to promote waste reduction and promote recycling. Also, Practice Greenhealth has recognized ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... ... health science curriculum , is pleased to announce a new online course entitled ... online course provides practical insights and evidence-based strategies for achieving optimal well-being and ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... that the introduction of school choice can promote economic development in economically distressed ... that has, according to the report, contributed to the economic development of the ...
(Date:6/20/2017)... ... 2017 , ... Leading dental clinicians, Drs. Ashlyn Price, Autumn Mayers and Ron ... Anatomage systems. With advanced digital images and modeling capabilities, the dentists identify all of ... restore oral health for those who are missing teeth in Midlothian, VA. ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... years ago today, the Monterey Pop Festival opened its gates ... Francisco "Summer of Love."  To celebrate the anniversary, Northern Light® ... market research portals that it will begin delivering to customers ... "Summer of Love (For Our Customers)."  ... Northern Light ...
(Date:6/14/2017)... WINSTON-SALEM, N.C. , June 14, 2017  In ... the Creative Startups pitch competition and came ... virtual reality platform is described by Forbes as "entering ... the American Medical Association as teaching "empathy to medical ... success, the startup was recently named a finalist for ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
Breaking Medicine Technology: